瀏覽量: 115
- 產(chǎn)品名稱: Research Grade Sotigalimab
- 產(chǎn)品貨號(hào): CSD68911
- 貨期: 現(xiàn)貨
- 價(jià)格與訂購: 2480
- 數(shù)量:
- 規(guī)格: 100μg
- 產(chǎn)品信息
- 如何訂購
Description
The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.icon
Catalog No.
CSD68911
Host species
Humanized
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
2.54 mg/ml
Purity
>95%
Clonality
Monoclonal
Isotype
IgG1-Kappa
Applications
Research Grade Sotigalimab Biosimilar
Target
Tumor necrosis factor receptor superfamily member 5,B-cell surface antigen CD40,Bp50,CD40L receptor,TNFRSF5,CDw40,CD40
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
Mammalian cells
Accession
P25942
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
Note
For research use only .Not suitable for clinical or therapeutic use.